Combination products don’t usually fail because the science is weak, they fail because teams hit avoidable friction: the wrong lead center, unclear expectations across centers, duplicated information, and quality system gaps that surface late.

Two recent FDA Office of Combination Products (OCP) updates give sponsors a clear opportunity to streamline:

• FDA revised its Pre-Request for Designation (Pre-RFD) guidance, clarifying how to obtain a preliminary FDA assessment early.
• FDA also issued a draft guidance on Cross-Center Master Files: Where to Submit, aimed at reducing confusion when master files support submissions where the lead center may vary or multiple centers need to review the information.

If you build these tools into your strategy early, you can reduce review churn and compress timelines.

1) Start with center alignment before you “overbuild” the dossier

The fastest way to waste months is to develop a submission package that doesn’t match the lead center’s expectations (or triggers extensive intercenter consults after the fact). FDA’s Pre-RFD process is designed to help sponsors get an early read from OCP on key questions that drive your path, especially jurisdiction and how the product will be handled.

Streamlining opportunity: Use Pre-RFD early enough that it influences development plans, not just labeling decisions.

2) Treat intercenter review as a predictable workstream, not a surprise

Combination product reviews often require consultative/collaborative input across centers, and FDA has long had an internal process intended to improve communication, timeliness, and consistency for those consults.

Streamlining opportunity: Build an “intercenter consult readiness” package up front:

• a clean constituent-part map (what’s drug/device/biologic and why),
• a crosswalk of where each required element lives in your submission,
• and a clear explanation of how you manage overlapping requirements (especially quality system controls).

3) Reduce duplicate review by using the master file strategy FDA is signaling

FDA’s Cross-Center Master Files: Where to Submit draft guidance specifically addresses master files intended to support more than one submission where the lead center may vary or multiple centers need to review the information.

Streamlining opportunity: If you have “reusable” elements (platform device components, common materials, common processes, supplier packages), structure them so they can be referenced cleanly across submissions while minimizing “where do we put this?” confusion during review.

4) Integrate quality system requirements early (because combo products don’t get “either/or” CGMP)

For combination products, 21 CFR Part 4 establishes which CGMP requirements apply and provides a framework for implementing a single CGMP operating system that covers the relevant drug/device/biologic requirements.

Streamlining opportunity: Don’t wait until “inspection readiness” to reconcile quality systems. Build a Part 4 operating model that:

• defines ownership across drug/device/biologic controls,
• makes interfaces auditable (complaints, CAPA, change control, supplier controls),
• and prevents late-stage remediation that derails submissions or launches.

A practical “streamline” checklist

If you want fewer loops with FDA, start here:

1. Pre-RFD early to align the regulatory “home base.”
2. Plan for intercenter review with a clean crosswalk and rationale package.
3. Use a cross-center master file strategy when content supports multiple submissions/centers.
4. Implement a Part 4-aligned CGMP operating system before it becomes a fire drill.

Bottom line

“Streamlining” combination product approval isn’t about cutting corners, it’s about cutting rework. FDA’s recent OCP updates reinforce a practical approach: align early on center expectations, reduce duplicated review through a clearer master-file strategy, and integrate Part 4 quality system requirements before they slow you down.

If you’re preparing a combination product submission (or cleaning up one that’s already in motion), QSN can help you build the pathway + quality system + submission crosswalk that prevents surprises and shortens timelines. Contact us now to discuss how.